Blood Cancer United receives $7.5 million Royalty Pharma donation for therapy program
AI Summary- Blood Cancer United and Royalty Pharma announced a $7.5 million donation for the Therapy Acceleration Program.
- TAP deploys donations as venture capital investments in early-stage blood cancer biotech companies.
- TAP has supported six therapies receiving FDA approval or National Comprehensive Cancer Network guideline inclusion.